Key result
Aneurysm treatment in patients over 80 with good grade aSAH showed no significant difference in survival after adjusting for frailty and comorbidity (HR 0.45; 95% CI 0.12-1.68; p=0.24).
Why the study?
An increasing proportion of aSAH occurs in older patients, who face widespread variability in treatment rates due to a different balance of risks.
Does aneurysm treatment improve functional outcome and survival in patients over 80 years old with good grade aSAH?
Cohort
Yes
Does aneurysm treatment improve functional outcome and survival in patients over 80 years old with good grade aSAH?
Hazard Ratio: 0.45 (95% CI 0.12–1.68)
p-value: p=0.24
Aneurysm treatment in patients over 80 with good grade aSAH does not show clear evidence of benefit or harm after adjusting for frailty and comorbidity.
Adjusted analysis shows no clear benefit from treatment in octogenarians with good-grade aSAH; hypothesis-generating and should not change practice.
Background An increasing proportion of aneurysmal subarachnoid haemorrhage (aSAH) occurs in older patients, in whom there is widespread variability in treatment rates due to a different balance of risks. Our aim was to compare outcomes of patients over 80 years old with good grade aSAH who underwent treatment of their aneurysm with those who did not.Methods Adult patients with good grade aSAH admitted to tertiary regional neurosciences centres contributing to the UK and Ireland Subarachnoid Haemorrhage Database (UKISAH) and a cohort of consecutive patients admitted from three regional cohorts were included for analysis. Outcomes were functional outcome at discharge, three months and survival at discharge.Results In the UKISAH, patients whose aneurysm was treated were more likely to have a favourable outcome at discharge (OR 2.34, CI 1.12–4.91, p = .02), at three months (OR 2.29, CI 1.11–4.76, p = .04), and lower mortality (10% vs. 29%, OR 0.83, CI 0.72–0.94, p < .01). In the regional cohort, a similar pattern was seen, but after correction for frailty and comorbidity there was no difference in survival (HR 0.45, CI 0.12–1.68, p = .24) or favourable outcome at discharge (OR 0.83, CI 0.23–2.94, p = .77) and at three months (OR 1.03, CI 0.25–4.29, p = .99).Conclusions Better early functional outcomes in those undergoing aneurysm treatment appear to be explained by differences in frailty and comorbidity. Therefore, treatment decisions in this patient group are finely balanced with no clear evidence overall of either benefit or harm in this cohort.
No takes yet. Share an insight, caveat, or question.
Ewbank et al. (2023) conducted a cohort in Aneurysmal subarachnoid haemorrhage. Aneurysm treatment vs. No aneurysm treatment was evaluated on Survival (adjusted for frailty and comorbidity) (HR 0.45, 95% CI 0.12-1.68, p=0.24). Aneurysm treatment in patients over 80 with good grade aSAH showed no significant difference in survival after adjusting for frailty and comorbidity (HR 0.45; 95% CI 0.12-1.68; p=0.24).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: